Foundayo's initial prescription count was notably lower than that of its rival. This is Eli Lilly's first FDA-approved weight-loss pill. The product in question is Eli Lilly's Foundayo, the company's ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

With every passing year—and each new season of Emily in Paris—Lily Collins reminds us that she and her character could actually not be more different. While the outré Emily Cooper never met a pattern ...

Lilly Pulitzer is known for rarely offering discounts on its highly sought-after apparel, but the brand is now kicking off its spring sale with rare markdowns on some of its most recognizable dresses, ...

Eli Lilly remains a Buy despite a recent 12% price decline, supported by strategic developments and valuation upside, even as it faces challenges. LLY faces near-term headwinds from Zepbound price ...

Discover Maryam Hampton's face shaving routine as she walks you through her method for achieving smooth, exfoliated skin at home. Using Mavericks Shave Cream and an eyebrow shaper, Maryam demonstrates ...

Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city. Indianapolis-based Lilly will celebrate 150 ...

Eli Lilly’s once-daily pill for weight loss got approval from U.S. drug regulators Wednesday. The all-clear sets up a battle with rival Novo Nordisk, which has been selling a pill version of its ...

Eli Lilly & Co.’s Zepbound is helping to solve one of the most intractable health challenges of our time: obesity. Now, the drugmaker is taking on another significant public health predicament: sleep ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." It’s impossible to imagine the 1960s Palm Beach scene without Lilly Pulitzer and Slim Aarons. Lilly, with ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...